Search

Your search keyword '"Paz-Ares, Luis"' showing total 1,959 results
Start Over Author "Paz-Ares, Luis" Publication Year Range Last 50 years
1,959 results on '"Paz-Ares, Luis"'

1. Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies

Author

Figarol, Sarah, Delahaye, Célia, Gence, Rémi, Doussine, Aurélia, Cerapio, Juan Pablo, Brachais, Mathylda, Tardy, Claudine, Béry, Nicolas, Asslan, Raghda, Colinge, Jacques, Villemin, Jean-Philippe, Maraver, Antonio, Ferrer, Irene, Paz-Ares, Luis, Kessler, Linda, Burrows, Francis, Lajoie-Mazenc, Isabelle, Dongay, Vincent, Morin, Clara, Florent, Amélie, Pagano, Sandra, Taranchon-Clermont, Estelle, Casanova, Anne, Pradines, Anne, Mazieres, Julien, Favre, Gilles, and Calvayrac, Olivier

Published
2024
Full Text
View/download PDF

2. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Author

Xie, Mingchao, Vuko, Miljenka, Rodriguez-Canales, Jaime, Zimmermann, Johannes, Schick, Markus, O’Brien, Cathy, Paz-Ares, Luis, Goldman, Jonathan W., Garassino, Marina Chiara, Gay, Carl M., Heymach, John V., Jiang, Haiyi, Barrett, J. Carl, Stewart, Ross A., Lai, Zhongwu, Byers, Lauren A., Rudin, Charles M., and Shrestha, Yashaswi

Published
2024
Full Text
View/download PDF

3. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Author

Segal, Neil H., Melero, Ignacio, Moreno, Victor, Steeghs, Neeltje, Marabelle, Aurelien, Rohrberg, Kristoffer, Rodriguez-Ruiz, Maria E., Eder, Joseph P., Eng, Cathy, Manji, Gulam A., Waterkamp, Daniel, Leutgeb, Barbara, Bouseida, Said, Flinn, Nick, Das Thakur, Meghna, Elze, Markus C., Koeppen, Hartmut, Jamois, Candice, Martin-Facklam, Meret, Lieu, Christopher H., Calvo, Emiliano, Paz-Ares, Luis, Tabernero, Josep, and Argilés, Guillem

Published
2024
Full Text
View/download PDF

6. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

Author

Tokito, Takaaki, Kolesnik, Oleksii, Sørensen, Jens, Artac, Mehmet, Quintela, Martín Lázaro, Lee, Jong-Seok, Hussein, Maen, Pless, Miklos, Paz-Ares, Luis, Leopold, Lance, Daniel, Jeannie, Munteanu, Mihaela, Samkari, Ayman, Xu, Lu, and Butts, Charles

Published
2024
Full Text
View/download PDF

7. Reply to P. de Boissieu et al

Author

Spigel, David R., Dowlati, Afshin, Chen, Yuanbin, Navarro, Alejandro, Chih-Hsin Yang, James, Stojanovic, Goran, Jove, Maria, Rich, Patricia, Andric, Zoran G., Wu, Yi-Long, Rudin, Charles M., Chen, Huanyu, Zhang, Li, Yeung, Stanley, Benzaghou, Fawzi, Paz-Ares, Luis, and Bunn, Paul A.

Published
2024
Full Text
View/download PDF

8. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

Author

Hernandez, Susana, Conde, Esther, Molero, Aida, Suarez-Gauthier, Ana, Martinez, Rebeca, Alonso, Marta, Plaza, Carlos, Camacho, Carmen, Chantada, Debora, Juaneda-Magdalena, Laura, Garcia-Toro, Enrique, Saiz-Lopez, Patricia, Rojo, Federico, Abad, Mar, Boni, Valentina, del Carmen, Sofia, Regojo, Rita Maria, Sanchez-Frias, Marina Esther, Teixido, Cristina, Paz-Ares, Luis, and Lopez-Rios, Fernando

Subjects
Thermo Fisher Scientific Inc., Bayer AG, Hoffmann-La Roche Inc. Roche Molecular Systems, Ventana Medical Systems Inc., Biological products industry, Immunohistochemistry, Genes, Colorectal cancer, Thyroid diseases, Muscle proteins, Lung cancer, Algorithms, Pharmaceutical industry, Sarcoma, Scientific equipment and supplies industry, Medical test kit industry, Medical equipment and supplies industry, Cancer, Algorithm, Health
Abstract

* Context.--The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a 'tumor-agnostic' manner. However, the identification of these patients is extremely challenging because the overall frequency of NTRK fusions is below 1%. Academic groups and professional organizations have released recommendations on the algorithms to detect NTRK fusions. The European Society for Medical Oncology proposal encourages the use of next-generation sequencing (NGS) if available, or alternatively immunohistochemistry (IHC) could be used for screening with NGS confirmation of all positive IHC results. Other academic groups have included histologic and genomic information in the testing algorithm. Objective.--To apply some of these triaging strategies for a more efficient identification of NTRK fusions within a single institution, so pathologists can gain practical insight on how to start looking for NTRK fusions. Design.--A multiparametric strategy combining histologic (secretory carcinomas of the breast and salivary gland; papillary thyroid carcinomas; infantile fibrosarcoma) and genomic (driver-negative non-small cell lung carcinomas, microsatellite instability-high colorectal adenocarcinomas, and wild-type gastrointestinal stromal tumors) triaging was put forward. Results.--Samples from 323 tumors were stained with the VENTANA pan-TRK EPR17341 Assay as a screening method. All positive IHC cases were simultaneously studied by 2 NGS tests, Oncomine Comprehensive Assay v3 and FoundationOne CDx. With this approach, the detection rate of NTRK fusions was 20 times higher (5.57%) by only screening 323 patients than the largest cohort in the literature (0.30%) comprising several hundred thousand patients. Conclusions.--Based on our findings, we propose a multiparametric strategy (ie, 'supervised tumor-agnostic approach') when pathologists start searching for NTRK fusions., In solid tumors, actionable gene fusions can be identified in a wide range of cancer types. (1) The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated [...]

Published
2024
Full Text
View/download PDF

9. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Author

Köbel, Martin, Kang, Eun‐Young, Weir, Ashley, Rambau, Peter F, Lee, Cheng‐Han, Nelson, Gregg S, Ghatage, Prafull, Meagher, Nicola S, Riggan, Marjorie J, Alsop, Jennifer, Anglesio, Michael S, Beckmann, Matthias W, Bisinotto, Christiani, Boisen, Michelle, Boros, Jessica, Brand, Alison H, Brooks‐Wilson, Angela, Carney, Michael E, Coulson, Penny, Courtney‐Brooks, Madeleine, Cushing‐Haugen, Kara L, Cybulski, Cezary, Deen, Suha, El‐Bahrawy, Mona A, Elishaev, Esther, Erber, Ramona, Fereday, Sian, Group, AOCS, Fischer, Anna, Gayther, Simon A, Barquin‐Garcia, Arantzazu, Gentry‐Maharaj, Aleksandra, Gilks, C Blake, Gronwald, Helena, Grube, Marcel, Harnett, Paul R, Harris, Holly R, Hartkopf, Andreas D, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y, Huang, Yajue, Jakubowska, Anna, Jimenez‐Linan, Mercedes, Jones, Michael E, Kennedy, Catherine J, Kluz, Tomasz, Koziak, Jennifer M, Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Longacre, Teri A, Lycke, Maria, Mateoiu, Constantina, McCauley, Bryan M, McGuire, Valerie, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Paz‐Ares, Luis, Ramón y Cajal, Teresa, Rothstein, Joseph H, Ruebner, Matthias, Schoemaker, Minouk J, Shah, Mitul, Sharma, Raghwa, Sherman, Mark E, Shvetsov, Yurii B, Singh, Naveena, Steed, Helen, Storr, Sarah J, Talhouk, Aline, Traficante, Nadia, Wang, Chen, Whittemore, Alice S, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Benitez, Javier, Berchuck, Andrew, Bowtell, David D, dos Reis, Francisco J Candido, Campbell, Ian, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Fasching, Peter A, Fortner, Renée T, García, María J, Goodman, Marc T, Goode, Ellen L, Gronwald, Jacek, Huntsman, David G, Karlan, Beth Y, Kelemen, Linda E, Kommoss, Stefan, Le, Nhu D, and Martin, Stewart G

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Ovarian Cancer, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Humans, Female, Tumor Suppressor Protein p53, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Carcinoma, Endometrioid, ovarian cancer, high-grade serous carcinoma, endometrioid, clear cell, TP53, p53, prognosis, AOCS Group, Clinical sciences
Abstract

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.

Published
2023

11. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Author

Desai, Jayesh, Alonso, Guzman, Kim, Se Hyun, Cervantes, Andres, Karasic, Thomas, Medina, Laura, Shacham-Shmueli, Einat, Cosman, Rasha, Falcon, Alejandro, Gort, Eelke, Guren, Tormod, Massarelli, Erminia, Miller, Jr., Wilson H., Paz-Ares, Luis, Prenen, Hans, Amatu, Alessio, Cremolini, Chiara, Kim, Tae Won, Moreno, Victor, Ou, Sai-Hong I., Passardi, Alessandro, Sacher, Adrian, Santoro, Armando, Stec, Rafal, Ulahannan, Susanna, Arbour, Kathryn, Lorusso, Patricia, Luo, Jia, Patel, Manish R., Choi, Yoonha, Shi, Zhen, Mandlekar, Sandhya, Lin, Mark T., Royer-Joo, Stephanie, Chang, Julie, Jun, Tomi, Dharia, Neekesh V., Schutzman, Jennifer L., and Han, Sae-Won

Published
2024
Full Text
View/download PDF

12. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Author

Weir, Ashley, Kang, Eun-Young, Meagher, Nicola S, Nelson, Gregg S, Ghatage, Prafull, Lee, Cheng-Han, Riggan, Marjorie J, Gentry-Maharaj, Aleksandra, Ryan, Andy, Singh, Naveena, Widschwendter, Martin, Alsop, Jennifer, Anglesio, Michael S, Beckmann, Matthias W, Berger, Jessica, Bisinotto, Christiani, Boros, Jessica, Brand, Alison H, Brenton, James D, Brooks-Wilson, Angela, Carney, Michael E, Cunningham, Julie M, Cushing-Haugen, Kara L, Cybulski, Cezary, Elishaev, Esther, Erber, Ramona, Fereday, Sian, Fischer, Anna, Paz-Ares, Luis, Gayarre, Javier, Gilks, Blake C, Grube, Marcel, Harnett, Paul R, Harris, Holly R, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda Y, Heublein, Sabine, Huang, Yajue, Huzarski, Tomasz, Jakubowska, Anna, Jimenez-Linan, Mercedes, Kennedy, Catherine J, Kommoss, Felix KF, Koziak, Jennifer M, Kraemer, Bernhard, Le, Nhu D, Lesnock, Jaime, Lester, Jenny, Lubiński, Jan, Menkiszak, Janusz, Ney, Britta, Olawaiye, Alexander, Orsulic, Sandra, Osorio, Ana, Robles-Díaz, Luis, Ruebner, Matthias, Shah, Mitul, Sharma, Raghwa, Shvetsov, Yurii B, Steed, Helen, Talhouk, Aline, Taylor, Sarah E, Traficante, Nadia, Vierkant, Robert A, Wang, Chen, Wilkens, Lynne R, Winham, Stacey J, Benitez, Javier, Berchuck, Andrew, Bowtell, David D, Candido dos Reis, Francisco J, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Fasching, Peter A, García, María J, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Huntsman, David G, Karlan, Beth Y, Kommoss, Stefan, Modugno, Francesmary, Schildkraut, Joellen M, Sinn, Hans-Peter, Staebler, Annette, Kelemen, Linda E, Ford, Caroline E, Menon, Usha, Pharoah, Paul DP, Köbel, Martin, and Ramus, Susan J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Ovarian Cancer, Clinical Research, Rare Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Humans, Female, Ovarian Neoplasms, Prognosis, Survival Analysis, RNA, Messenger, Cystadenocarcinoma, Serous, Biomarkers, Tumor, Forkhead Transcription Factors, AOCs group, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundRecently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC.MethodsTwo prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis.ResultsConsistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67-0.91, p 35% GMNN expression showed a trend for better outcomes, though this was not significant.ConclusionWe provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.

Published
2023

13. Telomere-based risk models for the early diagnosis of lung cancer

Author

Molina-Pinelo, Sonia, Ferrer Sánchez, Irene, Najarro, Pilar, Paz-Ares, Luis, Fernández, Luis, Castelló, Nila, Richart López, Luis Alberto, Rodríguez Gambarte, Juan Diego, Sanz García, Máximo, Salinas, Ana, Suárez, Rocío, Romero-Romero, Beatriz, Martín-Juan, José, Viñuela, María Eugenia, Butler, Ray G., and de Pedro, Nuria

Published
2024
Full Text
View/download PDF

14. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Author

Reck, Martin, Ciuleanu, Tudor-Eliade, Schenker, Michael, Bordenave, Stephanie, Cobo, Manuel, Juan-Vidal, Oscar, Reinmuth, Niels, Richardet, Eduardo, Felip, Enriqueta, Menezes, Juliana, Cheng, Ying, Mizutani, Hideaki, Zurawski, Bogdan, Alexandru, Aurelia, Carbone, David P., Lu, Shun, John, Thomas, Aoyama, Takekazu, Grootendorst, Diederik J., Hu, Nan, Eccles, Laura J., and Paz-Ares, Luis G.

Published
2024
Full Text
View/download PDF

16. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.

Author

Nishio, Makoto, Negrao, Marcelo Vailati, Arbour, Kathryn C., Burns, Timothy F., Cappuzzo, Federico, Dingemans, Anne-Marie C., Girard, Nicolas, Gronberg, Bjorn Henning, Hochmair, Maximilian, Leal, Ticiana, Lindsay, Colin R., Lu, Shun, Paz-Ares, Luis G., Reck, Martin, Sabari, Joshua K., Spira, Alexander I., William, William Nassib, Jr., Chen, Aaron, Visseren Grul, Carla M., and Peters, Solange

Published
2024
Full Text
View/download PDF

18. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

Author

Luke, Jason J., Long, Georgina V., Robert, Caroline, Carlino, Matteo S., Choueiri, Toni K., Haas, Naomi B., O’Brien, Mary, Paz-Ares, Luis, Peters, Solange, Powles, Thomas, Leiby, Melanie A., Lin, Jianxin, Zhao, Yujie, Krepler, Clemens, Perini, Rodolfo F., Catherine Pietanza, M., Samkari, Ayman, Gruber, Todd, Ibrahim, Nageatte, and Eggermont, Alexander M.M.

Published
2024
Full Text
View/download PDF

20. RET Fusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Published
2024
Full Text
View/download PDF

21. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Author

Li, Bob T, Smit, Egbert F, Goto, Yasushi, Nakagawa, Kazuhiko, Udagawa, Hibiki, Mazières, Julien, Nagasaka, Misako, Bazhenova, Lyudmila, Saltos, Andreas N, Felip, Enriqueta, Pacheco, Jose M, Pérol, Maurice, Paz-Ares, Luis, Saxena, Kapil, Shiga, Ryota, Cheng, Yingkai, Acharyya, Suddhasatta, Vitazka, Patrik, Shahidi, Javad, Planchard, David, and Jänne, Pasi A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lung, Lung Cancer, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Camptothecin, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Immunoconjugates, Lung Diseases, Interstitial, Lung Neoplasms, Male, Middle Aged, Pneumonia, Progression-Free Survival, Receptor, ErbB-2, Trastuzumab, DESTINY-Lung01 Trial Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundHuman epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively.MethodsWe conducted a multicenter, international, phase 2 study in which trastuzumab deruxtecan (6.4 mg per kilogram of body weight) was administered to patients who had metastatic HER2-mutant NSCLC that was refractory to standard treatment. The primary outcome was objective response as assessed by independent central review. Secondary outcomes included the duration of response, progression-free survival, overall survival, and safety. Biomarkers of HER2 alterations were assessed.ResultsA total of 91 patients were enrolled. The median duration of follow-up was 13.1 months (range, 0.7 to 29.1). Centrally confirmed objective response occurred in 55% of the patients (95% confidence interval [CI], 44 to 65). The median duration of response was 9.3 months (95% CI, 5.7 to 14.7). Median progression-free survival was 8.2 months (95% CI, 6.0 to 11.9), and median overall survival was 17.8 months (95% CI, 13.8 to 22.1). The safety profile was generally consistent with those from previous studies; grade 3 or higher drug-related adverse events occurred in 46% of patients, the most common event being neutropenia (in 19%). Adjudicated drug-related interstitial lung disease occurred in 26% of patients and resulted in death in 2 patients. Responses were observed across different HER2 mutation subtypes, as well as in patients with no detectable HER2 expression or HER2 amplification.ConclusionsTrastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).

Published
2022

22. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

Author

Rugo, Hope S, Kabos, Peter, Beck, J Thad, Jerusalem, Guy, Wildiers, Hans, Sevillano, Elena, Paz-Ares, Luis, Chisamore, Michael J, Chapman, Sonya C, Hossain, Anwar M, Chen, Yanyun, and Tolaney, Sara M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Cancer, Clinical Trials and Supportive Activities, Genetics, Clinical Research, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical sciences, Oncology and carcinogenesis, Epidemiology
Abstract

This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) without prior CDK4 and 6 inhibitor exposure. Patients were divided into two cohorts: treatment naïve (cohort 1) and pretreated (cohort 2). Patients received abemaciclib plus pembrolizumab with (cohort 1) or without (cohort 2) anastrozole over 21-day cycles. The primary objective was safety, and secondary objectives included efficacy and pharmacokinetics (PK). Cohort 1/2 enrolled 26/28 patients, respectively. Neutropenia (30.8/28.6%), AST increase (34.6/17.9%), ALT increase (42.3/10.7%), and diarrhea (3.8/10.7%) were the most frequent grade ≥3 adverse events in cohort 1/2, respectively. A total of two deaths occurred, which investigators attributed to treatment-related adverse events (AEs), both in cohort 1. Higher rates of all grade and grade ≥3 interstitial lung disease (ILD)/pneumonitis were observed compared to previously reported with abemaciclib and pembrolizumab monotherapy. The PK profiles were consistent between cohorts and with previous monotherapy studies. In cohorts 1/2, the overall response rate and disease control rate were 23.1/28.6% and 84.6/82.1%, respectively. Median progression-free survival and overall survivals were 8.9 (95% CI: 3.9-11.1) and 26.3 months (95% CI: 20.0-31.0) for cohort 2; cohort 1 data are immature. Abemaciclib plus pembrolizumab demonstrated antitumor activity, but high rates of ILD/pneumonitis and severe transaminase elevations occurred with/without anastrozole compared to the previous reporting. Benefit/risk analysis does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.

Published
2022

24. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Author

de Jager, Vincent D., Timens, Wim, Bayle, Arnaud, Botling, Johan, Brcic, Luka, Büttner, Reinhard, Fernandes, Maria Gabriela O., Havel, Libor, Hochmair, Maximilian J., Hofman, Paul, Janssens, Annelies, Johansson, Mikael, van Kempen, Léon, Kern, Izidor, Lopez-Rios, Fernando, Lüchtenborg, Margreet, Machado, José Carlos, Mohorcic, Katja, Paz-Ares, Luis, Popat, Sanjay, Ryška, Aleš, Taniere, Phillipe, Wolf, Jürgen, Schuuring, Ed, and van der Wekken, Anthonie J.

Published
2024
Full Text
View/download PDF

25. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

Author

Paz-Ares, Luis, Goto, Yasushi, Wan-Teck Lim, Darren, Halmos, Balazs, Chul Cho, Byoung, Cobo, Manuel, Luis González Larriba, José, Zhou, Caicun, Demedts, Ingel, Atmaca, Akin, Baka, Sofia, Mookerjee, Bijoyesh, Portella, Socorro, Zhu, Zewen, Wu, Jincheng, Demanse, David, Dharan, Bharani, and Reck, Martin

Published
2024
Full Text
View/download PDF

27. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Author

Vokes, Everett E., Mornex, Francoise, Sezer, Ahmet, Cheng, Ying, Fang, Jian, Baz, David Vicente, Cil, Timucin, Adjei, Alex A., Ahn, Myung-Ju, Barlesi, Fabrice, Felip, Enriqueta, Garon, Edward B., Audhuy, Francois, Ito, Rena, Sato, Masashi, Eggleton, S. Peter, Martin, Claudio Marcelo, Reck, Martin, Robinson, Clifford G., and Paz-Ares, Luis

Published
2024
Full Text
View/download PDF

28. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Author

Peters, Solange, Paz-Ares, Luis G., Reck, Martin, Carbone, David P., Brahmer, Julie R., Borghaei, Hossein, Lu, Shun, O’Byrne, Kenneth J., John, Thomas, Ciuleanu, Tudor-Eliade, Schenker, Michael, Bernabe Caro, Reyes, Nishio, Makoto, Cobo, Manuel, Lee, Jong-Seok, Zurawski, Bogdan, Pluzanski, Adam, Aoyama, Takekazu, Tschaika, Marina, Devas, Vipul, Grootendorst, Diederik J., and Ramalingam, Suresh S.

Published
2024
Full Text
View/download PDF

31. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Author

Macaya, Irati, Roman, Marta, Welch, Connor, Entrialgo-Cadierno, Rodrigo, Salmon, Marina, Santos, Alba, Feliu, Iker, Kovalski, Joanna, Lopez, Ines, Rodriguez-Remirez, Maria, Palomino-Echeverria, Sara, Lonfgren, Shane M., Ferrero, Macarena, Calabuig, Silvia, Ludwig, Iziar A., Lara-Astiaso, David, Jantus-Lewintre, Eloisa, Guruceaga, Elizabeth, Narayanan, Shruthi, Ponz-Sarvise, Mariano, Pineda-Lucena, Antonio, Lecanda, Fernando, Ruggero, Davide, Khatri, Purvesh, Santamaria, Enrique, Fernandez-Irigoyen, Joaquin, Ferrer, Irene, Paz-Ares, Luis, Drosten, Matthias, Barbacid, Mariano, Gil-Bazo, Ignacio, and Vicent, Silve

Published
2023
Full Text
View/download PDF

33. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Author

Cho, Byoung Chul, Lee, Jong Seok, Wu, Yi-Long, Cicin, Irfan, Dols, Manuel Cobo, Ahn, Myung-Ju, Cuppens, Kristof, Veillon, Rémi, Nadal, Ernest, Dias, Josiane Mourão, Martin, Claudio, Reck, Martin, Garon, Edward B., Felip, Enriqueta, Paz-Ares, Luis, Mornex, Francoise, Vokes, Everett E., Adjei, Alex A., Robinson, Clifford, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Audhuy, Francois, Chaudhary, Surendra, and Barlesi, Fabrice

Published
2023
Full Text
View/download PDF

34. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

Author

Le, Xiuning, Paz-Ares, Luis G., Van Meerbeeck, Jan, Viteri, Santiago, Galvez, Carlos Cabrera, Smit, Egbert F., Garassino, Marina, Veillon, Remi, Baz, David Vicente, Pradera, Jose Fuentes, Sereno, María, Kozuki, Toshiyuki, Kim, Young-Chul, Yoo, Seung Soo, Han, Ji-Youn, Kang, Jin-Hyoung, Son, Choon-Hee, Choi, Yoon Ji, Stroh, Christopher, Juraeva, Dilafruz, Vioix, Helene, Bruns, Rolf, Otto, Gordon, Johne, Andreas, and Paik, Paul K.

Published
2023
Full Text
View/download PDF

36. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Author

Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., and Brahmer, Julie R.

Published
2023
Full Text
View/download PDF

37. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Author

Carranza, Omar, Greco, Martin Alberto, Coward, Jim, Joshua, Anthony, Karapetis, Christos, Hart, Christopher, Zhang, Alison, Prenen, Hans, Goeminne, Jean-Charles, Machiels, Jean-Pascal, Rottey, Sylvie, Corassa, Marcelo, Molin, Graziela Zibetti Dal, Tiscoski, Katsuki, Jardim, Denis Leonardo Fontes, Mak, Milena, Fu, Wei, Yao, Herui, Huang, Jing, Jiang, Haiping, Qin, Shukui, Chen, Baoshi, Yan, Dong, Yang, Yu, Loriot, Yohann, Le Tourneau, Christophe, Penel, Nicolas, Salas, Sébastien, Blay, Jean-Yves, Brachet, Pierre-Emmanuel, Durando, Xavier, Emambux, Sheik, Ravaud, Alain, Folprecht, Gunnar, Arnold, Dirk, Schuler, Martin, Ahrens, Marit, Golf, Alexander, Haag, Georg Martin, Lordick, Florian, Desuki, Alexander, Cazzaniga, Marina, Ciardiello, Fortunato, Milella, Michele, Koyama, Takafumi, Hirooka, Yoshiki, Okamoto, Wataru, Aogi, Kenjiro, Kuboki, Yasutoshi, Lee, Jungyun, Kim, Sung-Bae, Ahn, Myung-Ju, Chang, Jong Hee, Kim, Yong-Man, Nam, Do-Hyun, Park, Jae-Sung, Lugowska, Iwona, Paz-Ares, Luis, Moreno, Victor, Cervantes, Andres, Calvo, Mariona, Falcon, Alejandro, Gonzalez, Antonio, Tabernero, Josep, Martinez Bueno, Alejandro, García-Corbacho, Javier, Longo, Federico, Yen, Chia-Jui, Chen, Jen-Shi, Hou, Ming-Feng, Chao, Yee, Rau, Kun-Ming, Chiu, Tai-Jan, Feng, Yin-Hsun, Hsu, Chih-Hung, Huang, Wen-Tsung, Lai, Kuan-Ming, Yeh, Su-peng, Palmer, Daniel, Minchom, Anna, Winter, Helen, Welsh, Liam, Plummer, Ruth, Iyer, Gopakumar, Gutierrez, Martin, Bilen, Mehmet, Arrowsmith, Edward, Pant, Shubham, Spigel, David Robert, Zandberg, Dan Paul, Doroshow, Deborah, Lu-Emerson, Christine, Moezi, Mehdi, Paulson, Scott, Reardon, David, Ward, Patrick, Chaves, Jorge, Grigg, Claud, Hussein, Atif, Manda, Sudhir, Monticelli, Michael, Qamar, Rubina, Richey, Stephen L, Tamura, David, Wilks, Sharon, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Reardon, David A, Massard, Christophe, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, and Sweiti, Hussein

Published
2023
Full Text
View/download PDF

39. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Author

Martins, Filipe Correia, Couturier, Dominique-Laurent, Paterson, Anna, Karnezis, Anthony N, Chow, Christine, Nazeran, Tayyebeh M, Odunsi, Adekunle, Gentry-Maharaj, Aleksandra, Vrvilo, Aleksandra, Hein, Alexander, Talhouk, Aline, Osorio, Ana, Hartkopf, Andreas D, Brooks-Wilson, Angela, DeFazio, Anna, Fischer, Anna, Hartmann, Arndt, Hernandez, Brenda Y, McCauley, Bryan M, Karpinskyj, Chloe, de Sousa, Christiani B, Høgdall, Claus, Tiezzi, Daniel G, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Keeney, Gary, Nelson, Gregg, Steed, Helen, Song, Honglin, Luk, Hugh, Benitez, Javier, Alsop, Jennifer, Koziak, Jennifer M, Lester, Jenny, Rothstein, Joseph H, de Andrade, Jurandyr M, Lundvall, Lene, Paz-Ares, Luis, Robles-Díaz, Luis, Wilkens, Lynne R, Garcia, Maria J, Intermaggio, Maria P, Alcaraz, Marie-Lyne, Brett, Mary A, Beckmann, Matthias W, Jimenez-Linan, Mercedes, Anglesio, Michael, Carney, Michael E, Schneider, Michael, Traficante, Nadia, Pejovic, Nadja, Singh, Naveena, Le, Nhu, Sinn, Peter, Ghatage, Prafull, Erber, Ramona, Edwards, Robert, Vierkant, Robert, Ness, Roberta B, Leung, Samuel, Orsulic, Sandra, Brucker, Sara Y, Kaufmann, Scott H, Fereday, Sian, Gayther, Simon, Winham, Stacey J, Kommoss, Stefan, Pejovic, Tanja, Longacre, Teri A, McGuire, Valerie, Rhenius, Valerie, Sieh, Weiva, Shvetsov, Yurii B, Whittemore, Alice S, Staebler, Annette, Karlan, Beth Y, Rodriguez-Antona, Cristina, Bowtell, David D, Goode, Ellen L, Høgdall, Estrid, Candido Dos Reis, Francisco J, Gronwald, Jacek, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, Fasching, Peter A, Crawford, Robin, Deen, Suha, Menon, Usha, Huntsman, David G, Köbel, Martin, Ramus, Susan J, Pharoah, Paul DP, and Brenton, James D

Subjects
Oncology & Carcinogenesis, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

BackgroundPTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.MethodsTumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests.ResultsDownregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value

Published
2020

40. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Author

Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D, and investigators, trial

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Neurosciences, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Antineoplastic Agents, Benzamides, Biomarkers, Tumor, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Gene Fusion, Humans, Indazoles, Male, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasms, Protein Kinase Inhibitors, Receptor, trkA, Receptor, trkB, Receptor, trkC, Receptors, Nerve Growth Factor, Time Factors, Treatment Outcome, trial investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundEntrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood-brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials.MethodsAn integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0-2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG (NCT02650401; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001).FindingsPatients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77-18·76). 31 (57%; 95% CI 43·2-70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred.InterpretationEntrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours.FundingIgnyta/F Hoffmann-La Roche.

Published
2020

41. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Author

Reck, Martin, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Cheng, Ying, Sakai, Hiroshi, Paz-Ares, Luis, Lu, Shun, John, Thomas, Sun, Xiaowu, Moisei, Aniela, Taylor, Fiona, Lawrance, Rachael, Zhang, Xiaoqing, Sylvester, Judi, Yuan, Yong, Blum, Steven I., Penrod, John R., and Carbone, David P.

Published
2023
Full Text
View/download PDF

43. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Author

de Langen, Adrianus Johannes, Johnson, Melissa L, Mazieres, Julien, Dingemans, Anne-Marie C, Mountzios, Giannis, Pless, Miklos, Wolf, Jürgen, Schuler, Martin, Lena, Hervé, Skoulidis, Ferdinandos, Yoneshima, Yasuto, Kim, Sang-We, Linardou, Helena, Novello, Silvia, van der Wekken, Anthonie J, Chen, Yuanbin, Peters, Solange, Felip, Enriqueta, Solomon, Benjamin J, Ramalingam, Suresh S., Dooms, Christophe, Lindsay, Colin R, Ferreira, Carlos Gil, Blais, Normand, Obiozor, Cynthia C, Wang, Yang, Mehta, Bhakti, Varrieur, Tracy, Ngarmchamnanrith, Gataree, Stollenwerk, Björn, Waterhouse, David, and Paz-Ares, Luis

Published
2023
Full Text
View/download PDF

44. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Cobo, Manuel, Bennouna, Jaafar, Schenker, Michael, Cheng, Ying, Juan-Vidal, Oscar, Mizutani, Hideaki, Lingua, Alejo, Reyes-Cosmelli, Felipe, Reinmuth, Niels, Menezes, Juliana, Jassem, Jacek, Protsenko, Svetlana, Richardet, Eduardo, Felip, Enriqueta, Feeney, Kynan, Zurawski, Bogdan, Alexandru, Aurelia, de la Mora Jimenez, Emmanuel, Dakhil, Shaker, Lu, Shun, Reck, Martin, John, Thomas, Hu, Nan, Zhang, Xiaoqing, Sylvester, Judi, Eccles, Laura J., Grootendorst, Diederik J., Balli, David, Neely, Jaclyn, and Carbone, David P.

Published
2023
Full Text
View/download PDF

45. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Author

Aix, Santiago Ponce, Ciuleanu, Tudor Eliade, Navarro, Alejandro, Cousin, Sophie, Bonanno, Laura, Smit, Egbert F, Chiappori, Alberto, Olmedo, Maria Eugenia, Horvath, Ildiko, Grohé, Christian, Farago, Anna F, López-Vilariño, José Antonio, Cullell-Young, Martin, Nieto, Antonio, Vasco, Noelia, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Carcereny, Enric, Roubec, Jaromir, Syrigos, Konstantinos, Lo, Gregory, Barneto, Isidoro, Pope, Anthony, Sánchez, Amparo, Kattan, Joseph, Zarogoulidis, Konstantinos, Waller, Cornelius F, Bischoff, Helge, Juan-Vidal, Oscar, Reinmuth, Niels, Dómine, Manuel, and Paz-Ares, Luis

Published
2023
Full Text
View/download PDF

46. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Author

Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong-Seok, Gainor, Justin F., Otterson, Gregory A., Audigier-Valette, Clarisse, Ready, Neal, Schenker, Michael, Linardou, Helena, Caro, Reyes Bernabe, Provencio, Mariano, Zurawski, Bogdan, Lee, Ki Hyeong, Kim, Sang-We, Caserta, Claudia, Ramalingam, Suresh S., Spigel, David R., Brahmer, Julie R., Reck, Martin, O’Byrne, Kenneth J., Girard, Nicolas, Popat, Sanjay, Peters, Solange, Memaj, Arteid, Nathan, Faith, Aanur, Nivedita, and Borghaei, Hossein

Published
2023
Full Text
View/download PDF

47. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Author

Subbiah, Vivek, Cassier, Philippe A., Siena, Salvatore, Garralda, Elena, Paz-Ares, Luis, Garrido, Pilar, Nadal, Ernest, Vuky, Jacqueline, Lopes, Gilberto, Kalemkerian, Gregory P., Bowles, Daniel W., Seetharam, Mahesh, Chang, Jianhua, Zhang, Hui, Green, Jennifer, Zalutskaya, Alena, Schuler, Martin, Fan, Yun, and Curigliano, Giuseppe

Published
2022
Full Text
View/download PDF

48. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

Author

Kim, Jun W, Marquez, Cesar P, Kostyrko, Kaja, Koehne, Amanda L, Marini, Kieren, Simpson, David R, Lee, Alex G, Leung, Stanley G, Sayles, Leanne C, Shrager, Joseph, Ferrer, Irene, Paz-Ares, Luis, Gephart, Melanie Hayden, Vicent, Silvestre, Cochran, Jennifer R, and Sweet-Cordero, E Alejandro

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lung Cancer, Lung, Aetiology, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Adenocarcinoma of Lung, Animals, Cell Line, Tumor, Cell Proliferation, Ciliary Neurotrophic Factor Receptor alpha Subunit, Cytokines, Gene Expression Regulation, Neoplastic, Humans, Interleukins, Mice, Mutation, Protein Binding, Proto-Oncogene Proteins p21(ras), Signal Transduction, Tumor Microenvironment, Tumor Suppressor Protein p53, Xenograft Model Antitumor Assays, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Proinflammatory cytokines in the tumor microenvironment can promote tumor growth, yet their value as therapeutic targets remains underexploited. We validated the functional significance of the cardiotrophin-like cytokine factor 1 (CLCF1)-ciliary neurotrophic factor receptor (CNTFR) signaling axis in lung adenocarcinoma (LUAD) and generated a high-affinity soluble receptor (eCNTFR-Fc) that sequesters CLCF1, thereby inhibiting its oncogenic effects. eCNTFR-Fc inhibits tumor growth in multiple xenograft models and in an autochthonous, highly aggressive genetically engineered mouse model of LUAD, driven by activation of oncogenic Kras and loss of Trp53. Abrogation of CLCF1 through eCNTFR-Fc appears most effective in tumors driven by oncogenic KRAS. We observed a correlation between the effectiveness of eCNTFR-Fc and the presence of KRAS mutations that retain the intrinsic capacity to hydrolyze guanosine triphosphate, suggesting that the mechanism of action may be related to altered guanosine triphosphate loading. Overall, we nominate blockade of CLCF1-CNTFR signaling as a novel therapeutic opportunity for LUAD and potentially for other tumor types in which CLCF1 is present in the tumor microenvironment.

Published
2019

49. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Author

Munster, Pamela, Mita, Monica, Mahipal, Amit, Nemunaitis, John, Massard, Christophe, Mikkelsen, Tom, Cruz, Cristina, Paz-Ares, Luis, Hidalgo, Manuel, Rathkopf, Dana, Blumenschein, George, Smith, David C, Eichhorst, Barbara, Cloughesy, Tim, Filvaroff, Ellen H, Li, Shaoyi, Raymon, Heather, de Haan, Hans, Hege, Kristen, and Bendell, Johanna C

Subjects
Clinical Research, Rare Diseases, Brain Disorders, Orphan Drug, Cancer, Clinical Trials and Supportive Activities, Patient Safety, Hematology, Pediatric Cancer, Pediatric, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, CC-115, mTORC1/mTORC2, mTOR inhibitor, DNA-PK inhibitor, Phase I study, Oncology and Carcinogenesis
Abstract

PurposeThis first-in-human Phase I study investigated the safety, pharmacokinetics (PK), pharmacodynamic profile, and preliminary efficacy of CC-115, a dual inhibitor of mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase.Patients and methodsPatients with advanced solid or hematologic malignancies were enrolled in dose-finding and cohort expansion phases. In dose-finding, once-daily or twice-daily (BID) ascending oral doses of CC-115 (range: 0.5-40 mg/day) in 28-day continuous cycles identified the maximum-tolerated dose for cohort expansion in 5 specified tumor types. Twelve additional patients with mixed solid tumors participated in a bioavailability substudy.ResultsForty-four patients were enrolled in the dose-finding cohort. Dose-limiting toxicity included thrombocytopenia, stomatitis, hyperglycemia, asthenia/fatigue, and increased transaminases. CC-115 10 mg BID was selected for cohort expansion (n=74) in which fatigue, nausea, and decreased appetite were the most frequent toxicities. Dose-proportional PK was found. CC-115 distributed to glioblastoma tissue (mean tumor/plasma concentration ratio: 0.713). Total exposure of CC-115 was similar under fasting and fed conditions. A patient with endometrial carcinoma remained in complete remission >4 years. Partial response (PR; n=2) and stable disease (SD; n=4) were reported in the bioavailability substudy; SD was reached in 53%, 22%, 21%, and 64% of patients with head and neck squamous cell carcinoma, Ewing sarcoma, glioblastoma multiforme, and castration-resistant prostate cancer, respectively. Chronic lymphocytic leukemia/small lymphocytic lymphoma showed 38% PR and 25% SD.ConclusionCC-115 was well-tolerated, with toxicities consistent with mTOR inhibitors. Together with biomarker inhibition and preliminary efficacy, oral CC-115 10 mg BID is a promising novel anticancer treatment.Clinical trial registrationNCT01353625.

Published
2019

50. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

Author

Wolin, Edward, Mita, Alain, Mahipal, Amit, Meyer, Tim, Bendell, Johanna, Nemunaitis, John, Munster, Pam N, Paz-Ares, Luis, Filvaroff, Ellen H, Li, Shaoyi, Hege, Kristen, de Haan, Hans, and Mita, Monica

Subjects
Humans, Neuroendocrine Tumors, Carcinoid Tumor, Gastrointestinal Neoplasms, Pyrazines, Administration, Oral, Cohort Studies, Maximum Tolerated Dose, Adult, Aged, Middle Aged, Female, Male, Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Administration, Oral, General Science & Technology
Abstract

Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Objectives were to evaluate tolerability, preliminary efficacy, and pharmacokinetic and biomarker profiles of CC-223. Forty-seven patients completed the study, with mean treatment duration of 378 days and mean dose of 26 mg; 26% of patients remained on the starting dose. Most frequent grade ≥3 toxicities were diarrhea (38%), fatigue (21%), and stomatitis (11%). By investigator, 3 of 41 evaluable patients (7%) showed partial response (PR) and 34 (83%) had stable disease (SD) for a disease control rate (DCR) of 90% (95% confidence interval [CI] 76.9-97.3%). Duration of PR was 125-401 days; median SD duration was 297 days (min-max, 50-1519 days). Median progression-free survival was 19.5 months (95% CI 10.4-28.5 months). Carcinoid symptoms of flushing, diarrhea, or both improved in 50%, 41%, and 39% of affected patients, respectively. For the first time, this study describes that a second-generation mTOR pathway inhibitor can result in highly durable tumor regression and control of NET carcinoid symptoms. The manageable safety profile, high DCR, and durable response, coupled with reduction in carcinoid symptoms refractory to SSA, make CC-223 a promising agent for further development.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results